SCHEMBL7141645

SCHEMBL7141645

CCOC(=O)Cn1c(C)c(Cl)nc(NN)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 2/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.39
GSR P00390 2/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.38
TPSAB1 Q15661 2/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
F2 P00734 2/20 0.37
F7 P08709 1/20 0.37
F3 P13726 1/20 0.37
PRSS1 P07477 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6848933 0.87 TNF (0.40) KDM4EALDH1A1MAPTPOLBTSHR
SCHEMBL7140320 0.84 F2 (0.47) KMT2AMEN1TPSAB1F2F7
SCHEMBL7139994 0.83 HSD17B10 (0.48) HSD17B10CYP1A2CYP2C9HPGDKDM4E
SCHEMBL7139116 0.75 KDM4E (0.45) HSD17B10CYP1A2CYP2C9HPGDKDM4E
SCHEMBL21248447 0.71 PDE4D (0.37) ALDH1A1TPSAB1POLB
SCHEMBL3247710 0.70 P2RX7 (0.43) CYP1A2CYP2C9CYP2C19ALDH1A1MAPT
SCHEMBL6849033 0.70 TNF (0.45) KDM4EALDH1A1KMT2AMEN1POLB
SCHEMBL3247707 0.69 F2 (0.60) TPSAB1F2F7F3PRSS1
SCHEMBL12636632 0.67 ALDH1A1 (0.48) HSD17B10CYP1A2CYP2C9HPGDKDM4E
SCHEMBL3240576 0.67 MEN1 (0.44) CYP1A2CYP2C9HPGDKDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506761-B1 Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
US-6506760-B1 Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
WO-2001079193-A2 SUBSTITUTED HYDRAZINYL HETEROAROMATIC INHIBITORS OF THROMBIN CORVAS INTERNATIONAL, INC. (US) 2001-10-25 WO disclosed